Limits...
The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas.

Ansari J, Chehrei A, Amini M, Alizade SH, Sanei MH - Iran J Cancer Prev (2011)

Bottom Line: Regardingrelationship between tumor grade and membranous Her2 , all patients with poorly differentiated tumors were Her2 negative but patients with moderate and well differentiated tumor had 18.1% and 19.6% Her2 reactivity respectively; there were no significant difference between groups statistically(P>0.05).Median overall survival was 27.25 and 46 months in Her2 negative and her2 positive cases respectively; there were no significant difference between groups statistically as well (P>0.05).Her2 reactivity has not relationship with tumor grade and lymph node involvement as well as tumor stage.

View Article: PubMed Central - PubMed

Affiliation: Dept. of Radiation Oncology, Aiatollah Khoansari Hospital, Arak University of Medical Sciences, Arak, Iran.

ABSTRACT

Background: Her2/neu is one of the epidermal growth factor receptors families and seems to have prognostic significance of some solid tumors. The objective of this study is to evaluate the possibility of Her2 expression in gastric cancers and the possible relationship of Her2 with tumor's clinicopathologic parameters and also its prognostic role.

Methods: This study was performed on 100 cases of gastric carcinoma with stage I b to III (according to TNM staging). Survival, recurrence date of patients, grade and lymph nodes involvement were assessed. Her2/neu expression was determined by immunohistochemical method on received sample blocks. Survival of patients with or without Her2-neu expression were evaluated by Kaplan- Meier method and compared with the log-rank test followed by multivariate analysis using Cox regression.

Results: Seven cases were 3+ membranous Her2 reactivity, 5 cases were 2+ and13 cases were 1+; also 75% of cases demonstrated no reactivity. Regardingrelationship between tumor grade and membranous Her2 , all patients with poorly differentiated tumors were Her2 negative but patients with moderate and well differentiated tumor had 18.1% and 19.6% Her2 reactivity respectively; there were no significant difference between groups statistically(P>0.05). Median overall survival was 27.25 and 46 months in Her2 negative and her2 positive cases respectively; there were no significant difference between groups statistically as well (P>0.05).

Conclusion: Her2 reactivity has not relationship with tumor grade and lymph node involvement as well as tumor stage. From the other point of view no significant correlation is found between Her2 expression and disease free survival or overall survival of gastric cancer patients.

No MeSH data available.


Related in: MedlinePlus

Disease free survivals as a function of membranous Her2 reactivity
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4551287&req=5

f3-IJCP-05-170: Disease free survivals as a function of membranous Her2 reactivity

Mentions: The median disease free survival (DFS) in the group with negative membranous her2 was 22.41(18.38-30.44) months and in positive her2 was 31.65(16.40-46.90) months; there was no statistically significant difference between groups (P>0.05) (Figure 3). Cox Regression analysis was performed to find out the effect of grade and stage but again no significant difference was detected between her2 reactivity status and DFS.


The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas.

Ansari J, Chehrei A, Amini M, Alizade SH, Sanei MH - Iran J Cancer Prev (2011)

Disease free survivals as a function of membranous Her2 reactivity
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4551287&req=5

f3-IJCP-05-170: Disease free survivals as a function of membranous Her2 reactivity
Mentions: The median disease free survival (DFS) in the group with negative membranous her2 was 22.41(18.38-30.44) months and in positive her2 was 31.65(16.40-46.90) months; there was no statistically significant difference between groups (P>0.05) (Figure 3). Cox Regression analysis was performed to find out the effect of grade and stage but again no significant difference was detected between her2 reactivity status and DFS.

Bottom Line: Regardingrelationship between tumor grade and membranous Her2 , all patients with poorly differentiated tumors were Her2 negative but patients with moderate and well differentiated tumor had 18.1% and 19.6% Her2 reactivity respectively; there were no significant difference between groups statistically(P>0.05).Median overall survival was 27.25 and 46 months in Her2 negative and her2 positive cases respectively; there were no significant difference between groups statistically as well (P>0.05).Her2 reactivity has not relationship with tumor grade and lymph node involvement as well as tumor stage.

View Article: PubMed Central - PubMed

Affiliation: Dept. of Radiation Oncology, Aiatollah Khoansari Hospital, Arak University of Medical Sciences, Arak, Iran.

ABSTRACT

Background: Her2/neu is one of the epidermal growth factor receptors families and seems to have prognostic significance of some solid tumors. The objective of this study is to evaluate the possibility of Her2 expression in gastric cancers and the possible relationship of Her2 with tumor's clinicopathologic parameters and also its prognostic role.

Methods: This study was performed on 100 cases of gastric carcinoma with stage I b to III (according to TNM staging). Survival, recurrence date of patients, grade and lymph nodes involvement were assessed. Her2/neu expression was determined by immunohistochemical method on received sample blocks. Survival of patients with or without Her2-neu expression were evaluated by Kaplan- Meier method and compared with the log-rank test followed by multivariate analysis using Cox regression.

Results: Seven cases were 3+ membranous Her2 reactivity, 5 cases were 2+ and13 cases were 1+; also 75% of cases demonstrated no reactivity. Regardingrelationship between tumor grade and membranous Her2 , all patients with poorly differentiated tumors were Her2 negative but patients with moderate and well differentiated tumor had 18.1% and 19.6% Her2 reactivity respectively; there were no significant difference between groups statistically(P>0.05). Median overall survival was 27.25 and 46 months in Her2 negative and her2 positive cases respectively; there were no significant difference between groups statistically as well (P>0.05).

Conclusion: Her2 reactivity has not relationship with tumor grade and lymph node involvement as well as tumor stage. From the other point of view no significant correlation is found between Her2 expression and disease free survival or overall survival of gastric cancer patients.

No MeSH data available.


Related in: MedlinePlus